Billerica, MA – Millipore says it has completed its acquisition of Serologicals following approval by Serologicals’ shareholders. The company says the acquisition will provide it with combined annual revenues of approximately $1.4 billion, based on 2006 full-year projections.
“The strategic combination of Millipore and Serologicals will enable us to leverage the complementary capabilities and resources of both companies,” says Martin Madaus, chairman & CEO of Millipore. “We are gaining high-value, differentiated products in important growth segments such as drug discovery products and services, nucleic function, stem cell research, and cell culture supplements.
Have your say: